视网膜前膜对糖尿病性黄斑水肿患者雷珠单抗治疗效果的影响。
Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema.
作者信息
Ercalik Nimet Yesim, Imamoglu Serhat, Kumral Esra Turkseven, Yenerel Nursal Melda, Bardak Handan, Bardak Yavuz
机构信息
Ophthalmology Department, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
出版信息
Arq Bras Oftalmol. 2016 Nov-Dec;79(6):373-375. doi: 10.5935/0004-2749.20160106.
PURPOSE
: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME).
METHODS
: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated.
RESULTS
: In the study group, although the CMT was significantly reduced following the first injection (p<0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p<0.001) and improvement in BCVA (p<0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group.
CONCLUSIONS
: We observed a negative short-term influence of the ERM on IVR treatment for DME.
目的
探讨视网膜前膜（ERM）对玻璃体内注射雷珠单抗（IVR）治疗糖尿病性黄斑水肿（DME）的影响。
方法
本回顾性研究纳入48例DME患者的56只眼，分为两组：伴有ERM的DME（研究组）和单纯DME（对照组）。评估中心黄斑厚度（CMT）和最佳矫正视力（BCVA）的变化。
结果
研究组中，首次注射后CMT虽显著降低（p<0.001），但BCVA无显著改善（p=0.296）。然而，首次注射后，对照组CMT显著降低（p<0.001）且BCVA改善（p<0.001）。然而，对照组BCVA的改善与研究组结果无显著差异。
结论
我们观察到ERM对IVR治疗DME有短期负面影响。
Zotero 插件